QLS2313
Phase 1Small molecule
Qilu Pharmaceutical Co., Ltd.QLS2313 is one of 4 small molecule programs targeting Relapsed/Refractory Hematological Malignancies. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Relapsed/refractory Hematological Malignancies
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Invivo CAR-T
CChongqing Precision Biotech Co., Ltd
Phase 1
QLS2313
Qilu Pharmaceutical Co., Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QLS2313. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details